[Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors]
{{output}}
This single-center retrospective analysis enrolled 32 patients with relapsed/refractory (R/R) B-cell lymphoma who received glofitamab-containing regimens at Beijing Tongren Hospital. Study endpoints were progression-free survival (PFS), overall survival (OS), ... ...
